Table 3.

Thirteen trials of monotherapy vs. combination therapy, categorized according to whether patients experienced benefits or not during combination therapy.

Benefit as assessed by improved outcomes
a) Substantial quality of life or mood or neurocognitive benefit
Bunevicius, 1999
Nygaard
b) Some quality of life or mood or neurocognitive benefit
Escobar-Morreale (5 μg T3)
Escobar-Morreale (7.5 μg T3)
Saravanan*
c) No quality of life or mood or neurocognitive benefit
Appelhof (T4 + T3, 10:1 ratio)
Appelhof (T4 + T3, 5:1 ratio)
Bunevicius, 2002
Clyde
Fadeyev
Kaminski
Rodriguez
Sawka
Siegmund
Walsh

^*Showed benefit at 6 months but not at 12 months.